Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder featured with multi-organ benign tumours. Disruption of TSC1/TSC2 complex suppression on mammalian/mechanistic target of rapamycin (mTOR) signalling causes TSC. Hyperactive mTOR-mediated negative feedback regulation of AKT partially contributes to the benign nature of TSCassociated tumours. In this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1/TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma-derived Tsc2-deficient cells, genetically modified mouse TSC models, and clinical samples. TSC1/TSC2 complex upregulation of OPN expression is mediated by transcription factor SOX9 in an mTOR-independent manner. Moreover, ablation of OPN by deficient TSC1/TSC2 complex contributed to inactivation of AKT in TSC cells. Lastly, the abundance of OPN dictated the potency of cell proliferation and tumour development. Therefore, loss of TSC1/TSC2 complex led to mTOR-independent inhibition of AKT at least partially through downregulation of the SOX9-OPN signalling cascade. We suggest that the decreased SOX9-OPN-AKT signalling pathway safeguard against the development of malignant tumours in TSC patients. †
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease with benign tumour formation in the brain, kidney, skin, and other organs (1) (2) (3) (4) . It is caused by inactivating mutation in either TSC1 or TSC2 gene. TSC2 and TSC1 form a functional protein complex (5) . As a binding partner, TSC1 stabilizes TSC2 through inhibiting the degradation of TSC2 mediated by the ubiquitin/proteasomes pathway (6) . Loss of either TSC1 or TSC2 activates mammalian/mechanistic target of rapamycin (mTOR) (7) (8) (9) (10) (11) . mTOR, a highly conserved serine/threonine protein kinase, is a key regulator of many cellular processes, such as metabolism, cell proliferation, and survival (12) (13) (14) . It can associate with different binding partners to form two functional complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is sensitive to rapamycin whereas mTORC2 is rapamycin-insensitive (15) (16) (17) . Autophagy suppression (18) and the low somatic mutation rate (19) have been reported to contribute to the benign feature of TSCassociated tumours. Moreover, loss of TSC1/TSC2 complex inactivates AKT, which was also considered to be responsible for the benign nature of TSC-related tumours (7, (20) (21) (22) (23) . Mechanistically, hyperactivation of mTORC1 led to downregulation of IRS, PDGFRs and upregulation of Grb10, PTEN, and storeoperated Ca 2þ signalling, which have been demonstrated to be involved in the inactivation of AKT (22) (23) (24) (25) . However, additional signalling pathways, especially mTOR-independent pathways, might contribute to reduced AKT activity in TSC-associated tumours remain to be elucidated. Osteopontin (OPN), a secreted glycoprotein, plays a vital role in many biological processes, such as cell proliferation, apoptosis, metastasis and angiogenesis (26) (27) (28) . By binding to its receptors, CD44 and integrins, OPN activates numerous signalling pathways, including ERK, JNK, and PI3K/AKT pathways (27, 29) . OPN is differentially expressed in a variety of cancers (30, 31) , but its expression status and function in the development of TSC-associated tumours remain poorly understood.
In this study, we have demonstrated that loss of TSC1/TSC2 complex suppressed the expression of OPN in an mTORindependent manner. Overexpression of OPN led to enhanced cell proliferation, increased colony formation, and accelerated tumorigenesis in Tsc2 -/-MEFs. In contrast, knockdown of OPN resulted in the suppression of cell proliferation, inhibition of colony formation, and the attenuation of the tumour growth in Tsc2 þ/þ MEFs.
Moreover, loss of TSC1/TSC2 complex suppressed OPN expression through downregulation of the transcription factor SOX9. Notably, the downregulation of OPN expression contributed to inhibition of AKT activity due to loss of function of TSC1/TSC2 complex. Therefore, decreased OPN level in TSC lesions may mute the malignant potential of tumours by compromising AKT activity.
Results

TSC1/TSC2 complex positively regulates the expression of OPN
Previous data have shown that OPN plays a critical role in tumorigenesis (32) . To investigate whether OPN plays a role in the tumour development caused by loss of TSC1/TSC2 complex, we first checked the level of OPN in Tsc2 þ/þ and Tsc2 -/-MEFs.
Unexpectedly, Tsc2 -/-MEFs showed a dramatically downregulated expression of OPN as compared to Tsc2 þ/þ MEFs (Fig. 1A left panel). qRT-PCR analysis further revealed that the downregulation of OPN was occurred at the transcriptional level ( Fig. 1A middle panel) . Moreover, we determined using ELISA that OPN levels were also significantly lower in the cell culture supernatants of Tsc2 -/-MEFs than those of Tsc2 þ/þ MEFs (Fig. 1A right panel). The ectopic expression of TSC2 restored the expression and secretion of OPN in Tsc2 -/-MEFs (Fig. 1B) .
Consistently, reintroduction of TSC2 also rescued the expression and secretion of OPN in rat uterine leiomyoma-derived Tsc2-null ELT3 cells (Fig. 1C) . Since TSC1 stabilizes TSC2 as a binding partner (6), we postulate that TSC1 was also involved in the regulation of OPN. As expected, TSC1 depletion led to markedly reduced OPN expression and secretion in Tsc2 þ/þ MEFs (Fig. 1D) . Furthermore, two TSC genetic mouse models were employed to verify the relationship between TSC1/TSC2 complex and OPN in vivo. As shown in Fig. 1E , OPN expression was decreased in kidney tumours from Tsc2 þ/-mice compared with para-cancerous tissues. OPN was also drastically reduced in the brain tissue from neural-specific TSC1 knockout mice (Tsc1
Nes-cre þ ), compared to that from the control mice (Tsc1 f/þ Nescre þ ) (Fig. 1F ). In addition, we evaluated the expression level of OPN in clinical samples by analysing mRNA microarray data of angiofibromas and periungual fibromas, which are known as typical skin lesions in TSC patients (33, 34) , in comparison with normal skin from the Gene Expression Omnibus database (GEO accession number GSE9715, deposited by Darling TN (35)). As expected, OPN was decreased in angiofibroma and periungual fibroma tissues, in comparison to the normal tissues ( Fig. 1G and Supplementary Material, Fig. S1A ). Therefore, these data indicate that TSC1/TSC2 complex is a positive regulator of OPN.
Loss of TSC1/TSC2 complex downregulation of OPN is mTOR-independent
We next explored the mechanism underlying significantly reduced expression of OPN by TSC1/TSC2 complex deficiency.
Since loss of function of TSC1/TSC2 complex resulted in hyperactivation of mTOR (20) . Moreover, aberrantly activated mTOR is considered to be the major cause of tumour formation in TSC, hence we predicted that mTOR may be involved in the regulation of OPN expression. To investigate whether OPN reduction was directly due to mTOR activation, Tsc2-null MEFs were treated with rapamycin, a specific inhibitor of mTORC1, for up to 48 h. As depicted in the Fig. 2A , rapamycin treatment led to a marked reduction of p-S6 (a marker of mTORC1 activity) in Tsc2 -/-MEFs. Interestingly, the level of OPN was almost no change in response to rapamycin treatment in a timedependent manner ( Fig. 2A) . A consistent result was obtained in ELT3 cells treated with rapamycin (Fig. 2B) . Furthermore, we treated these cells with different concentrations of KU-0063794, an mTOR kinase inhibitor that could suppress both mTORC1 and mTORC2 activities, for up to 48 h. There was also no change of OPN levels in response to KU-0063794 treatment in Tsc2 -/-MEFs and ELT3 cells ( Fig. 2C and D Loss of TSC1/TSC2 complex downregulates SOX9 expression independent of mTOR SOX9, a transcription factor, plays a critical role in tumorigenesis (36,37). We next determined whether SOX9 expression is controlled by TSC1/TSC2 complex. As shown in Fig. 3a , both the protein and mRNA levels of SOX9 were dramatically decreased in Tsc2 -/-MEFs compared to Tsc2 þ/þ MEFs. Ectopic expression of TSC2 reversed the protein and mRNA levels of SOX9 in Tsc2-null MEFs (Fig. 3B) . Furthermore, immunofluorescence analysis showed that the nuclear expression of SOX9 was significantly decreased in Tsc2 -/-MEFs as compared with the control cells (Fig. 3C) . Moreover, the expression of SOX9 was upregulated in ELT3 cells in response to ectopic expression of TSC2 (Fig. 3D) . Reduction of TSC1 markedly reduced SOX9 expression in Tsc2 Fig. S3 ). In addition, SOX9 expression was reduced in kidney tumours from Tsc2 þ/-mice compared with paratumour tissues (Fig. 3E) . SOX9 was drastically decreased in the brain tissue from Tsc1 f/f Nes-cre þ mice as compared to that from Tsc1 f/þ Nes-cre þ mice (Fig. 3F) . By analysing mRNA microarray data from the Gene Expression Omnibus database (GEO accession number GSE9715, deposited by Darling TN (35)), we also found that the abundance of SOX9 was decreased in angiofibroma and periungual fibroma tissues compared with the normal tissues in 3 of 4 patients ( Fig. 3G and Supplementary Material, Fig. S1B ). Collectively, these data indicate that TSC1/TSC2 complex is a positive regulator of SOX9. To explore whether mTOR is implicated in the regulation of SOX9 downstream of TSC1/TSC2 complex, we treated Tsc2 -/-MEFs or ELT3 cells with rapamycin or KU-0063794. As shown in Fig. 3H , there was almost no change on the expression of SOX9 in response to rapamycin or KU-0063794 in these two cells. Moreover, we examined SOX9 protein levels in Tsc2 -/-MEFs or ELT3 cells with knockdown of mTOR, Raptor, or Rictor. As depicted in Fig. 3I , siRNAs targeting mTOR, Raptor, or Rictor led to no change on SOX9 expression. Taken together, these data show that loss of TSC1/TSC2 complex downregulation of SOX9 expression is also mTOR-independent.
Loss of TSC1/TSC2 complex-mediated downregulation of SOX9 attenuates OPN/AKT signalling pathway In order to determine whether SOX9 directly regulated OPN expression, we analysed SOX9 consensus binding sites in the promoter of the mouse OPN gene. A putative SOX9 binding site (-2939/-2930; TTAACAATGG) was identified in the promoter of OPN gene (Fig. 4G) . To examine the transcriptional ability of SOX9 on OPN gene, four repeats of the potential SOX9 response element were inserted into a luciferase reporter plasmid. The recombinant reporter plasmid (pOPNLuc) was then co-transfected into 293T cells with pLXIN-SOX9 or empty control vector. Increased luciferase activity in cells transduced with SOX9 suggested a significant transcriptional activation of OPN gene by SOX9 (Fig. 4H) . Moreover, an for 12 h were subjected to ChIP assay using an antibody against SOX9. Normal rabbit IgG antibody was used as the negative control. qRT-PCR was performed to amplify regions surrounding the putative SOX9-binding region (PBR) and a nonspecific SOX9-binding region (NBR). The data were plotted as the ratio of immunoprecipitated DNA subtracting nonspecific binding to IgG vs. total input DNA. **P<0.01.
elevated luciferase activity was also observed in SOX9-transduced Tsc2-null cells (Fig. 4I) . Significantly, the enhanced transcriptional activity was impaired when the putative SOX9-binding site was mutated (Fig. 4I ). Chromatin immunoprecipitation (ChIP) analysis revealed that the direct binding of SOX9 to this putative SOX9-binding site within the promoter of OPN gene was significantly attenuated in Tsc2 OPN promotes cell proliferation, colony formation, and tumour growth
To evaluate the potential role of OPN in tumour formation caused by loss of function of TSC1/TSC2 complex, we first investigated the effect of OPN on cell growth of Tsc2-null MEFs. As shown in Fig. 5A and B, overexpression of OPN significantly accelerated cell proliferation and enhanced colony formation in Representative images were shown. Scale bar, 500 lm. *P<0.05; **P<0.01; ***P<0.001. (E and F) Tsc2 -/-MEFs transduced with pLV-OPN or pLV lentiviruses (E) and Tsc2
MEFs transduced with shSc or shOPN 2 lentiviruses (F) were inoculated subcutaneously into nude mice, and followed for tumour formation (left panels) and mice survival (right panels). (G and H) Tumour tissues from nude mice were embedded with paraffin and then subjected to immunohistochemistry analysis. Representative images were shown. Scale bar, 50 lm.
þ MEFs (Fig. 5C and D) . Next, we explored the role of OPN in tumourigenicity. As shown in Fig. 5E , overexpression of OPN enhanced tumourigenic capacity of Tsc2 -/-MEFs in nude mice.
Moreover, reduction of OPN blunted tumorigenesis of Tsc2 þ/ þ MEFs (Fig. 5F ). Additionally, IHC analysis of tumour tissues from nude mice revealed that tumour tissues derived from cells with overexpressed OPN exhibited increased expression of Ki-67 and vice versa ( Fig. 5G and H) , indicating that OPN promoted cell proliferation in vivo. Collectively, OPN is a pro-oncogenic factor and downregulation of OPN constrained the tumorigenesis caused by loss of TSC1/TSC2 complex.
Reduction of OPN ablates AKT activity in TSC1/TSC2 complex-deficient cells
It has been demonstrated that OPN can promote the activation of AKT (29, 38, 39) . Since loss of TSC1/TSC2 complex led to inhibition of AKT activity and our work here showed that OPN is a downstream effector of TSC1/TSC2 complex, it is reasonable to postulate that loss of TSC1/TSC2 complex suppresses AKT activity at least partially through downregulating OPN expression. As expected, treatment with soluble OPN protein led to an increase in the protein level of p-AKT in Tsc2 -/-MEFs (Fig. 6A) .
Furthermore, ectopically expressed OPN resulted in activation of AKT in Tsc2 -/-MEFs (Fig. 6B) , and depletion of OPN expression impaired AKT activity in the control cells (Fig. 6C) . To determine whether OPN plays a critical role in AKT activation in vivo, tumour tissues derived from Tsc2 -/-MEFs with overexpressed OPN and Tsc2 þ/þ MEFs with reduced OPN were subjected to analysis of p-AKT levels. As shown in Fig. 6D , elevation of OPN expression was accompanied by increased p-AKT levels in tumour tissues. Moreover, tumour tissues derived from Tsc2 þ/þ MEFs with knockdown of OPN exhibited a remarkable decrease in the levels of OPN and p-AKT as compared to the control tissues (Fig. 6E) . Taken together, OPN is pivotal for AKT activation and loss of TSC1/TSC2 complex downregulation of AKT activity is mediated, at least in part, by decreased OPN expression.
Discussion
In the present study, we have demonstrated that the decreased OPN expression led to inhibition of AKT activation and constrained the tumour development induced by loss of TSC1/TSC2 complex in an mTOR-independent manner. Moreover, the transcription factor SOX9 was involved in the downregulation of OPN expression due to loss of TSC1/TSC2 complex. AKT is involved in multiple cellular processes, including cell proliferation, survival, and differentiation. Aberrantly activated AKT has been illustrated in many cancers (40, 41) . However, AKT activity was suppressed in TSC tumours, largely due to the negative feedback inhibition of AKT by hyperactivated mTORC1 caused by loss of TSC1/TSC2 complex. Reduction of IRS and PDGFRs or upregulation of Grb10, PTEN, and store-operated Ca 2þ signalling have been implicated in the attenuation of PI3K/ AKT signalling by activation of mTORC1. Restoration of PI3K/ AKT signalling activity by overexpression of PDGFRb enhances the tumourigenicity of cells with loss of TSC1/TSC2 complex (22) . However, inhibition of mTORC1 by rapamycin only partially restored AKT activity in Tsc2 -/-MEFs in contrast to Tsc2 þ/ þ MEFs (23, 25, 42) , indicating that loss of TSC1/TSC2 complex could also reduce AKT activity in an mTOR-independent manner. We demonstrate here that the inhibition of SOX9-OPN signalling cascade in an mTOR-independent manner was identified as a novel mechanism for the reduced AKT activity in TSC lesions. The findings shed new light on the understanding of the benign tumour formation in TSC patients. OPN is frequently dysregulated in cancers. The elevated OPN expression has been shown to correlate with the tumour progression (32) . Numerous studies have demonstrated that activation of AKT plays a crucial role in OPN-mediated tumorigenesis. In this study, we also demonstrated that AKT is a critical downstream effector of OPN (Fig. 6) . Moreover, our work, consistent with other studies, revealed that OPN promotes cell growth in vitro and in vivo (Fig. 5 ). More importantly, we found that loss of TSC1/TSC2 complex led to dramatically reduced expression of OPN (Fig. 1) . Therefore, we propose that decreased OPN/AKT signalling pathway contributes to the benign feature of TSCassociated tumours. In line with OPN, loss of TSC1/TSC2 complex also downregulated expression of CD44, an OPN receptor (Supplementary Material, Fig. S4 ). Therefore, loss of TSC1/TSC2 may decrease OPN expression and consequently suppress AKT in a CD44-dependent manner.
Although TSC is featured with benign tumours in multiple organs, some TSC patients develop renal cell carcinomas (RCC) at low frequency and lymphangioleiomyomatosis (LAM) in 1/3 of female patients (2, 43) . Interestingly, a previous study revealed that OPN levels were elevated in the blood of patients with LAM, a disease with neoplastic features (44) . Meanwhile, elevated CD44v6, a splice variant of CD44 associated with metastasis, was observed in LAM cells (44) . Therefore, the upregulated OPN/CD44v6 signalling pathway may contribute to the metastatic potential of LAM cells. Our study demonstrates that the reduced OPN safeguarded against the development of malignant tumours in TSC patients. Similar to TSC lesions, OPN was downregulated in hydatidiform mole, a benign tumour that develops in the uterus (45) .
Given that OPN plays a crucial role in tumorigenesis, the transcriptional regulation of OPN has been intensively investigated recently. Several transcription factors have been reported to be implicated in the regulation of OPN, including c-Myb, Runx2, Osx, and MEF (46) (47) (48) (49) . Here we demonstrated that SOX9, as a novel downstream target of TSC1/TSC2 complex, bound to a consensus binding site (-2939/-2930; TTAACAATGG) in the promoter of mouse OPN gene and directly regulates the transcription of OPN gene (Fig. 4) . This result was consistent with a previous study which reported that SOX9 transcriptionally increases the expression of OPN in rat and human hepatic stellate cells (50) . Dramatically decreased expression of OPN in the brain tissue of Tsc1 f/f Nes-cre þ mouse was observed (Fig. 1F) , but the expression of SOX9 was restricted to ventricular zone (Fig. 3F) ,
indicating that other molecules may be involved in the regulation of OPN expression downstream of TSC1/TSC2 complex except SOX9. In addition, dysregulated AKT/TSC/mTOR pathway has been commonly reported in mesothelioma (51, 52) . Moreover, OPN was a promising diagnostic marker for mesothelioma (53) . Therefore, it remains to be further determined whether TSC-SOX9-OPN-AKT signalling cascade is implicated in the pathogenesis of mesothelioma. There is evidence that SOX9 upregulates AKT activity (54, 55) , but the mechanisms remain largely obscure. Here we illuminated that SOX9 and OPN were significantly decreased due to loss of TSC1/TSC2 complex (Figs 1 and 3) . SOX9 positively regulated the activity of AKT (Fig. 4) . Moreover, our study showed that AKT was a critical downstream effector of OPN (Fig. 6) , and we also determined that SOX9 transcriptionally enhanced OPN expression (Fig. 4) . Thus, a new mechanism was established for the link between SOX9 and AKT, in which SOX9 increases AKT activity through upregulation of OPN.
In summary, we demonstrated that loss of TSC1/TSC2 complex led to inhibition of AKT activity through downregulation of SOX9-OPN signalling cascade in an mTOR-independent way (Fig. 6F) . Decreased expression of OPN ameliorated the tumourigenicity of cells with loss of TSC1/TSC2 complex. Our study provides new insights into the regulation of AKT activity by TSC1/ TSC2 complex, and contribute to explicate why TSC patients predispose to develop benign tumours, but not malignant tumours.
Materials and Methods
Reagents and plasmids
Rapamycin and KU-0063794 were purchased from Selleck Chemicals (Houston, TX, USA). Recombinant mouse OPN protein was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Lipofectamine 2000 and 4-12% Bis-Tris Nu-PAGE gels were from Life Technologies (Carlsbad, CA, USA). pLXIN retroviral vector and pLXIN-TSC2 vector have been described previously (56).
Cell culture
All the mouse embryonic fibroblasts (MEFs) and rat uterine leiomyoma-derived Tsc2-null ELT3 cells used in this study have been described previously (7, (57) (58) (59) . PT67 packaging cells were purchased from Clontech (Palo Alto, CA, USA). HEK 293T cells were obtained from ATCC (Manassas, VA, USA). ELT3 cells were cultured in DMEM/F12 (1:1) with 10% FBS. The other cells were cultured in DMEM with 10% FBS. All cells were incubated at 37 C in 5% CO 2 . The mouse SOX9 coding sequence was obtained by PCR from mouse embryonic fibroblasts (MEFs) cDNA pools and inserted into the pLXIN vector. Production of retroviruses and subsequent generation of stable gene expression cell lines have been described previously (57) .
Immunoblotting
Whole cell lysates used in immunoblot analysis were prepared using high detergent lysis buffer with protease and phosphatase inhibitors. Lysates were normalized to protein concentration with a Bradford assay (Bio-Rad, Hercules, CA, USA). Immunoblot analysis of protein expression was performed as described previously (60) . Antibodies against TSC1 (#6935), S6 (#2217), phospho-S6 (Ser235/236) (#4857), phospho-AKT (ser473) (#4060), mTOR (#2983), Raptor (#2280), and Rictor (#2114) were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibodies against OPN (ab91655) were obtained from Abcam (Cambridge, UK). Antibodies against TSC2 (sc893), SOX9 (sc20095), and bactin (sc47778) were obtained from Santa Cruz Biotechnology. The CD44 antibody (AF6127) was purchased from R&D Systems (Minneapolis, MN, USA).
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol (Life Technologies) according to the manufacturer's instructions. RNA was converted to cDNA using the PrimeScript TM RT Reagent Kit (TaKaRa, Shiga, Japan). PCR amplification was performed using Power SYBR 
Immunofluorescence assay
Cells were seeded on coverslips overnight and fixed with 4% formaldehyde, and followed by the treatment of 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for permeabilization and blocked with 2% bovine serum albumin for 40 minutes. To visualize the expression of SOX9, the coverslips were incubated with anti-SOX9 antibody (sc20095) for overnight and then incubated with FITC-conjugated secondary antibody (Cell Signaling Technology) for 1 h. The fluorescence staining was observed with a fluorescence microscope (Olympus, Tokyo, Japan). DAPI (Sigma-Aldrich) was used to visualize cell nucleus.
Reporter constructs and luciferase reporter assay pOPN-Luc was generated by replacing the cis-acting STAT3 enhancer element in pSTAT3-TA-Luc (Beyotime Institute of Biotechnology, Haimen, China) with the potential SOX9 response element (TTAACAATGG Â 4) from the mouse OPN gene promoter. The sequences of the two oligonucleotides for SOX9 response element were as follows: forward: 5'-TCGAGTTAACAA TGGTTAACAATGGTTAACAATGGTTAACAATGGA-3' and reverse: 5'-GATCTCCATTGTTAACCATTGTTAACCATTGTTAACC ATTGTTAAC-3'. After annealing of the two oligonucleotides, the double-stranded DNA fragments were cloned into the pSTAT3-TA-Luc digested by the Xho I and Bgl II to generate the pOPNLuc. The potential SOX9 response element 5'-TTAACAATGG-3' was changed to 5'-TTAATGCTGG-3' for the construction of a mutant luciferase reporter plasmid (pOPNmut-Luc). The primers were as follows: forward: 5'-TCGAGTTAATGCTGG TTAATGCTGGTTAATGCTGGTTAATGCTGGA-3' and reverse: 5'-GATCTCCAGCATTAACCAGCATTAACCAGCATTAACCAGCATT AAC-3'. The control plasmid pRL-TK (renilla luciferase reporter) was obtained from Promega (Madison, WI, USA). For the luciferase assay, cells were cultured in triplicate to 80% confluence in 24-well plates and transfected with the promoter constructs (200 ng) in combination with the plasmid pRL-TK (20 ng) as an internal control. Luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega).
Chromatin immunoprecipitation (ChIP) assay
Immunoprecipitation experiments with an anti-SOX9 antibody (Abcam, ab3697) were performed to identify protein-DNA interactions with the SimpleChIP 
Lentivirus production and cell transduction
The lentiviral plasmid GV367 expressing mouse OPN (NM_001204203.1) and the negative control plasmid were purchased from GeneChem (Shanghai, China) and were termed as pLV-OPN and pLV, respectively. HEK 293T cells were transfected with pLV-OPN or pLV together with packaging vectors (pVSVG, pREV, and pMDL). Cell culture supernatants were harvested 48 h after transfection and then used for infection of target cells. The mission shRNA lentiviral transduction particles were purchased from GeneChem (Shanghai, China). The target sequences were as follows: shOPN The infection of mission shRNA lentiviruses particles and selection of positive colonies were performed according to the manufacturer's instructions.
Cell proliferation assay
Cells were seeded into 96-well plates in triplicate at a density of 1 Â 10 3 /well. The cell proliferation was monitored for 4 days and examined using an MTT assay as described previously (23) .
Enzyme-linked immunosorbent assay (ELISA)
In brief, cells were seeded in 12-well plates in triplicates, and replaced with 1 ml of serum free medium after 12 h, and continued to culture for 36 h. Cell culture supernatants were harvested, and OPN levels were measured with Quantikine Mouse/ Rat OPN ELISA kits (R&D Systems) according to the manufacturer's instructions.
Soft agar assay
Tsc2 -/-MEFs transduced with pLV or pLV-OPN lentiviruses and Tsc2 þ/þ MEFs transduced with shSc or shOPN lentiviruses were used to explore in vitro colony-forming ability. The colony formation assay was performed as described previously (58) .
Mouse kidney tumour assessment
Kidney cystadenoma tissues and para-cancerous tissues from three heterozygous Tsc2 deletion mice (C57BL/6, Tsc2 þ/-) (61) were harvested and then subjected to immunoblotting.
Mouse brain assessment
Nes-cre mice and Tsc1-floxed mice (Tsc1 f/f ) were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Tsc1 f/f mice were first crossed with Nes-cre mice to obtain Tsc1 f/þ Nes-cre þ mice, which were then back-crossed with Tsc1 f/f mice to obtain brain-specific Tsc1 knockout Tsc1 f/f Nes-cre þ mice. Tsc1 f/f Nes-cre þ mice were dead within 24 h after birth (62) . Mouse embryos were isolated from the pregnant mouse generated from breeding between Tsc1 f/þ Nes-cre þ male and Tsc1 f/f female mice and then subjected to immunohistochemistry analysis.
Induction of subcutaneous tumours in nude mice
Eight male nude mice (BALB/c, 6 weeks old) were used in each cohort. Tumour development was assessed over 80-day periods following subcutaneous inoculation of 1 Â 10 7 Tsc2 -/-MEFs expressing OPN or LV and 5 Â 10 6 Tsc2 þ/þ MEFs expressing shOPN 2 or shSc in 200 ml of DMEM. Subcutaneous tumours were established in immunodeficient nude mice as described previously (22, 63) . Mice were euthanized when tumour size was bigger than 1000 mm 3 , there was ulceration over tumour, or weight loss greater than 10% occurred. All animals were maintained and used in strict accordance with the guidelines of the Animal Center of Anhui Medical University.
Immunohistochemistry (IHC) analysis
Tissue samples were fixed in 4% paraformaldehyde and embedded in paraffin. Immunohistochemical staining was carried out as described previously (25) . OPN antibody (Santa Cruz, sc-21742) and Ki-67 antibody (Abcam, ab16667) were used for immunohistochemistry analysis.
Statistical analysis
The Kaplan-Meier log-rank test was used for the analysis of tumour growth and mice survival data. Differences between two groups were analysed using the two-tailed Student's t-test. One-way ANOVA was used to evaluate differences in the experiment involving multiple comparisons. Data represent mean 6 SD of triplicate samples. Statistical significance was defined as P < 0.05.
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